BioNexus Gene Lab Corp 8-K

What Happened BioNexus Gene Lab Corp (BGLC) filed an 8-K on December 30, 2025 reporting the results of its 2025 Annual Meeting of Stockholders. The company announced that all director nominees were elected, its 2025 Equity Incentive Plan was approved by shareholders, JP Centurion & Partners PLT was ratified as the independent registered public accounting firm for fiscal 2025, and a proposal to permit adjournment for additional proxy solicitation was approved.

Key Details

• Director elections:
  • Su-Leng Tan Lee — For: 972,902.8; Against: 4,485.5; Abstentions: 300
  • Muhammad Azrul bin Abdul Hamid — For: 972,902.8; Against: 4,485.5; Abstentions: 300
  • Jook Yuen Low — For: 971,641.8; Against: 4,485.5; Abstentions: 1,561
  • Chee Keong Yap — For: 972,902.8; Against: 4,485.5; Abstentions: 300
• 2025 Equity Incentive Plan approved — For: 966,759.8; Against: 10,628.5; Abstentions: 300.
• Auditor ratified — JP Centurion & Partners PLT for fiscal year ending Dec 31, 2025 — For: 973,284.3; Against: 3,402.5; Abstentions: 1,001.5.
• Adjournment proposal approved (to allow additional proxy solicitation if needed) — For: 966,489.3; Against: 9,647.5; Abstentions: 1,551.5.

Why It Matters These votes finalize the company’s board slate and governance actions for the coming year. Approval of the 2025 Equity Incentive Plan authorizes the company to grant equity-based compensation (which can affect dilution and executive incentives). Ratifying the independent auditor confirms the firm that will conduct the company’s financial audits for 2025. For investors, these outcomes mean management and governance matters were largely supported by shareholders and the company has the board, auditor and equity plan in place for its fiscal 2025 operations.